<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22210578</article-id><article-id pub-id-type="pmc">3263888</article-id><article-id pub-id-type="publisher-id">1272</article-id><article-id pub-id-type="doi">10.2337/dc11-1272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Insulin Secretion and Its Determinants in the Progression of Impaired Glucose Tolerance to Type 2 Diabetes in Impaired Glucose-Tolerant Individuals</article-title><subtitle>The Finnish Diabetes Prevention Study</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Mello</surname><given-names>Vanessa D.F.</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Lindström</surname><given-names>Jaana</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Johan</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ilanne-Parikka</surname><given-names>Pirjo</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Keinänen-Kiukaanniemi</surname><given-names>Sirkka</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff9"><sup>9</sup></xref><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sundvall</surname><given-names>Jouko</given-names></name><degrees>MSC</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Laakso</surname><given-names>Markku</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tuomilehto</surname><given-names>Jaakko</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff12"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Uusitupa</surname><given-names>Matti</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff13"><sup>13</sup></xref></contrib><aff id="aff1"><sup>1</sup>Institute of Public Health and Clinical Nutrition, Clinical Nutrition, University of Eastern Finland, Kuopio, Finland</aff><aff id="aff2"><sup>2</sup>Department of Health Promotion and Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland</aff><aff id="aff3"><sup>3</sup>Hjelt Institute, Department of Public Health, University of Helsinki, Helsinki, Finland</aff><aff id="aff4"><sup>4</sup>Folkhälsan Research Center, Helsinki, Finland</aff><aff id="aff5"><sup>5</sup>Unit of General Practice, Helsinki University Central Hospital, Helsinki, Finland</aff><aff id="aff6"><sup>6</sup>Vaasa Central Hospital, Vaasa, Finland</aff><aff id="aff7"><sup>7</sup>Diabetes Centre, Finnish Diabetes Association, Tampere, Finland</aff><aff id="aff8"><sup>8</sup>Science Centre, Pirkanmaa Hospital District, Tampere University Hospital, Tampere, Finland</aff><aff id="aff9"><sup>9</sup>Institute of Health Sciences, University of Oulu, Oulu, Finland</aff><aff id="aff10"><sup>10</sup>Unit of General Practice, Oulu University Hospital and Oulu Health Centre, Oulu, Finland</aff><aff id="aff11"><sup>11</sup>Department of Medicine, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland</aff><aff id="aff12"><sup>12</sup>South Ostrobothnia Central Hospital, Seinäjoki, Finland</aff><aff id="aff13"><sup>13</sup>Research Unit, Kuopio University Hospital, Kuopio, Finland</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Vanessa D.F. de Mello, <email>vanessa.laaksonen@uef.fi</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2012</year></pub-date><volume>35</volume><issue>2</issue><fpage>211</fpage><lpage>217</lpage><history><date date-type="received"><day>5</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>7</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>© 2012 by the American Diabetes Association.</copyright-statement><copyright-year>2012</copyright-year><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="211.pdf"></self-uri><abstract><sec id="s1"><title><offsets xml_i="6392" xml_f="6401" txt_i="11" txt_f="20">OBJECTIVE</offsets></title><p><offsets xml_i="6412" xml_f="6862" txt_i="21" txt_f="471">We investigated the effect of early-phase insulin secretion on the incidence of type 2 diabetes in individuals with impaired glucose tolerance (IGT) participating in the Finnish Diabetes Prevention Study (DPS). We examined how a lifestyle intervention affected early-phase insulin secretion (ratio of total insulin area under the curve [AUC] and total glucose AUC [AIGR] from 0 to 30 min) during a 4-year follow-up intervention trial and whether AIGR</offsets><sub><offsets xml_i="6867" xml_f="6871" txt_i="471" txt_f="475">0–30</offsets></sub><offsets xml_i="6877" xml_f="6940" txt_i="475" txt_f="538"> response was modified by insulin sensitivity (IS) and obesity.</offsets></p></sec><sec id="s2"><title><offsets xml_i="6970" xml_f="6997" txt_i="540" txt_f="567">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="7008" xml_f="7137" txt_i="568" txt_f="697">A total of 443 participants with IGT originally randomized to a lifestyle intervention or control group were studied. IS and AIGR</offsets><sub><offsets xml_i="7142" xml_f="7146" txt_i="697" txt_f="701">0–30</offsets></sub><offsets xml_i="7152" xml_f="7331" txt_i="701" txt_f="880"> were estimated from an oral tolerance glucose test administered annually during the 4-year follow-up trial and were related to the risk of diabetes onset over a 6-year follow-up.</offsets></p></sec><sec id="s3"><title><offsets xml_i="7361" xml_f="7368" txt_i="882" txt_f="889">RESULTS</offsets></title><p><offsets xml_i="7379" xml_f="7425" txt_i="890" txt_f="936">Lifestyle intervention resulted in higher IS (</offsets><italic><offsets xml_i="7433" xml_f="7434" txt_i="936" txt_f="937">P</offsets></italic><offsets xml_i="7443" xml_f="7477" txt_i="937" txt_f="971"> = 0.02) and lower unadjusted AIGR</offsets><sub><offsets xml_i="7482" xml_f="7486" txt_i="971" txt_f="975">0–30</offsets></sub><offsets xml_i="7492" xml_f="7494" txt_i="975" txt_f="977"> (</offsets><italic><offsets xml_i="7502" xml_f="7503" txt_i="977" txt_f="978">P</offsets></italic><offsets xml_i="7512" xml_f="7643" txt_i="978" txt_f="1109"> = 0.08) during the 4-year follow-up. A higher IS and a lower BMI during the follow-up were associated with a lower unadjusted AIGR</offsets><sub><offsets xml_i="7648" xml_f="7652" txt_i="1109" txt_f="1113">0–30</offsets></sub><offsets xml_i="7658" xml_f="7711" txt_i="1113" txt_f="1166"> during the follow-up, independently of study group (</offsets><italic><offsets xml_i="7719" xml_f="7720" txt_i="1166" txt_f="1167">P</offsets></italic><offsets xml_i="7729" xml_f="7857" txt_i="1167" txt_f="1292"> &lt; 0.001). A greater increase in IS on the median cutoff point of a 0.69 increase was associated with higher IS-adjusted AIGR</offsets><sub><offsets xml_i="7862" xml_f="7866" txt_i="1292" txt_f="1296">0–30</offsets></sub><offsets xml_i="7872" xml_f="7895" txt_i="1296" txt_f="1319"> during the follow-up (</offsets><italic><offsets xml_i="7903" xml_f="7904" txt_i="1319" txt_f="1320">P</offsets></italic><offsets xml_i="7913" xml_f="7971" txt_i="1320" txt_f="1378"> = 0.002). In multivariate models, IS and IS-adjusted AIGR</offsets><sub><offsets xml_i="7976" xml_f="7980" txt_i="1378" txt_f="1382">0–30</offsets></sub><offsets xml_i="7986" xml_f="8043" txt_i="1382" txt_f="1439"> were both inversely associated with diabetes incidence (</offsets><italic><offsets xml_i="8051" xml_f="8052" txt_i="1439" txt_f="1440">P</offsets></italic><offsets xml_i="8061" xml_f="8180" txt_i="1440" txt_f="1556"> &lt; 0.001). Participants who progressed to type 2 diabetes were more obese and had lower IS and Matsuda IS index-AIGR</offsets><sub><offsets xml_i="8185" xml_f="8189" txt_i="1556" txt_f="1560">0–30</offsets></sub><offsets xml_i="8195" xml_f="8216" txt_i="1560" txt_f="1581"> than nonprogressors.</offsets></p></sec><sec id="s4"><title><offsets xml_i="8246" xml_f="8257" txt_i="1583" txt_f="1594">CONCLUSIONS</offsets></title><p><offsets xml_i="8268" xml_f="8519" txt_i="1595" txt_f="1846">Our results indicate that the reduction in the risk of developing type 2 diabetes after lifestyle intervention is related to the improvement of IS along with weight loss. Improved IS may also have beneficial effects on preservation of β-cell function.</offsets></p></sec></abstract></article-meta></front><body><p><offsets xml_i="8572" xml_f="8661" txt_i="1855" txt_f="1944">Genetic and environmental factors both contribute to the development of type 2 diabetes (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8692" xml_f="8693" txt_i="1944" txt_f="1945">1</offsets></xref><offsets xml_i="8700" xml_f="9005" txt_i="1945" txt_f="2250">). Current evidence indicates that an underlying defect in insulin secretion in the presence of insulin resistance leads to the development of diabetes. Impaired glucose tolerance (IGT) is already characterized by impaired first-phase insulin secretion, a determinant for further progression to diabetes (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="9036" xml_f="9037" txt_i="2250" txt_f="2251">2</offsets></xref><offsets xml_i="9044" xml_f="9045" txt_i="2251" txt_f="2252">–</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="9076" xml_f="9077" txt_i="2252" txt_f="2253">5</offsets></xref><offsets xml_i="9084" xml_f="9086" txt_i="2253" txt_f="2255">).</offsets></p><p><offsets xml_i="9093" xml_f="9218" txt_i="2256" txt_f="2381">Lifestyle changes involving healthy diet, moderate weight loss, and increased physical activity reduce the risk of diabetes (</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="9249" xml_f="9250" txt_i="2381" txt_f="2382">6</offsets></xref><offsets xml_i="9257" xml_f="9258" txt_i="2382" txt_f="2383">–</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="9289" xml_f="9290" txt_i="2383" txt_f="2384">8</offsets></xref><offsets xml_i="9297" xml_f="9624" txt_i="2384" txt_f="2711">). The extent to which this is due to reduced insulin resistance or improved insulin secretion is not known. Improvements in insulin secretion and insulin sensitivity after 1 year of lifestyle intervention were associated with lower diabetes risk in the Diabetes Prevention Program (DPP) study during a follow-up of 3.2 years (</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="9655" xml_f="9656" txt_i="2711" txt_f="2712">6</offsets></xref><offsets xml_i="9663" xml_f="9906" txt_i="2712" txt_f="2955">). In a substudy of the Finnish Diabetes Prevention Study (DPS) in persons with IGT who did not progress to diabetes, insulin secretion measured during a frequently sampled intravenous glucose tolerance test (IVGTT) remained stable for years (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="9937" xml_f="9938" txt_i="2955" txt_f="2956">9</offsets></xref><offsets xml_i="9945" xml_f="10148" txt_i="2956" txt_f="3159">). However, data from long-term intervention trials on the mechanisms that may result in improvement of glucose metabolism and prevention of diabetes associated with healthy lifestyle changes are scarce.</offsets></p><p><offsets xml_i="10155" xml_f="10561" txt_i="3160" txt_f="3566">Therefore, we investigated the effect of surrogate indices of early-phase insulin secretion and insulin sensitivity from an oral glucose tolerance test (OGTT) on diabetes incidence in individuals participating in the Finnish DPS. We also evaluated whether insulin secretion response in the OGTT was modified by insulin sensitivity and obesity, and how lifestyle intervention may affect the β-cell function.</offsets></p><sec id="s5"><title><offsets xml_i="10585" xml_f="10612" txt_i="3567" txt_f="3594">RESEARCH DESIGN AND METHODS</offsets></title><sec id="s6"><title><offsets xml_i="10640" xml_f="10657" txt_i="3595" txt_f="3612">Design of the DPS</offsets></title><p><offsets xml_i="10668" xml_f="10984" txt_i="3613" txt_f="3929">The DPS was a randomized, controlled, multicenter study in Finland between the years 1993 and 2000 (ClinicalTrials.govNCT00518167) in which 522 individuals with IGT were randomized into an intervention or control group in five centers. The study design and methods of the DPS have been reported in detail elsewhere (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="11015" xml_f="11016" txt_i="3929" txt_f="3930">8</offsets></xref><offsets xml_i="11023" xml_f="11024" txt_i="3930" txt_f="3931">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="11056" xml_f="11058" txt_i="3931" txt_f="3933">10</offsets></xref><offsets xml_i="11065" xml_f="11250" txt_i="3933" txt_f="4118">). The study protocol was approved by the ethics committee of the National Public Health Institute of Helsinki, Finland, and all of the study participants gave written informed consent.</offsets></p><p><offsets xml_i="11257" xml_f="11305" txt_i="4119" txt_f="4164">The main inclusion criteria were BMI &gt;25 kg/m</offsets><sup><offsets xml_i="11310" xml_f="11311" txt_i="4164" txt_f="4165">2</offsets></sup><offsets xml_i="11317" xml_f="11756" txt_i="4165" txt_f="4604">, age 40–64 years, and IGT based on the mean values of two OGTTs according to the World Health Organization 1985 criteria. Random allocation to one of the two study groups was stratified according to the center, sex, and the 2-h glucose at the screening OGTT. At baseline and at annual visits, individuals completed a medical history questionnaire and underwent a physical examination that included anthropometric measurements and an OGTT.</offsets></p><p><offsets xml_i="11763" xml_f="12006" txt_i="4605" txt_f="4848">For this study, analyses were limited to those 443 participants who had at least one measurement of glucose and insulin at 30 min during the 4-year follow-up trial because samples for 30-min insulin and glucose were not collected at baseline (</offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1"><offsets xml_i="12123" xml_f="12143" txt_i="4848" txt_f="4868">Supplementary Fig. 1</offsets></ext-link><offsets xml_i="12154" xml_f="12372" txt_i="4868" txt_f="5086">). The median length of the study was 4 years (range 1–6). During this 4-year follow-up period, all participants were undergoing the randomized intervention. Participants who developed diabetes discontinued the study (</offsets><italic><offsets xml_i="12380" xml_f="12381" txt_i="5086" txt_f="5087">n</offsets></italic><offsets xml_i="12390" xml_f="12397" txt_i="5087" txt_f="5094"> = 12, </offsets><italic><offsets xml_i="12405" xml_f="12406" txt_i="5094" txt_f="5095">n</offsets></italic><offsets xml_i="12415" xml_f="12426" txt_i="5095" txt_f="5106"> = 14, and </offsets><italic><offsets xml_i="12434" xml_f="12435" txt_i="5106" txt_f="5107">n</offsets></italic><offsets xml_i="12444" xml_f="12586" txt_i="5107" txt_f="5249"> = 19 at years 2, 3, and 4, respectively), and the measurements from their previous annual visits before diagnosis were used for the analyses.</offsets></p></sec><sec id="s7"><title><offsets xml_i="12616" xml_f="12650" txt_i="5251" txt_f="5285">Program for the intervention group</offsets></title><p><offsets xml_i="12661" xml_f="12717" txt_i="5286" txt_f="5342">The intervention program has been described previously (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="12748" xml_f="12749" txt_i="5342" txt_f="5343">8</offsets></xref><offsets xml_i="12756" xml_f="12757" txt_i="5343" txt_f="5344">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="12789" xml_f="12791" txt_i="5344" txt_f="5346">10</offsets></xref><offsets xml_i="12798" xml_f="13455" txt_i="5346" txt_f="6003">). Briefly, the individuals in the intervention group received individually tailored dietary advice aiming at reducing weight and the intake of total and saturated fat and increasing the intake of dietary fiber. Individuals in the intervention group also received individual guidance to increase their level of physical activity. The most intensive period of intervention was during the first year of the study, when the participants showed improvement in main lifestyle indicators (e.g., body weight and glucose and lipid concentrations). The control group received general advice on the benefits of weight reduction, physical activity, and a healthy diet.</offsets></p></sec><sec id="s8"><title><offsets xml_i="13485" xml_f="13516" txt_i="6005" txt_f="6036">Glucose and insulin homeostasis</offsets></title><p><offsets xml_i="13527" xml_f="13775" txt_i="6037" txt_f="6285">During 1993 to 1996, a baseline 2-h OGTT was performed (75 g glucose load). In the OGTT performed during follow-up visits starting from the middle of 1996, samples were also taken for 30-min insulin and glucose and for 60-min glucose measurements (</offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1"><offsets xml_i="13892" xml_f="13912" txt_i="6285" txt_f="6305">Supplementary Fig. 1</offsets></ext-link><offsets xml_i="13923" xml_f="13925" txt_i="6305" txt_f="6307">).</offsets></p></sec><sec id="s9"><title><offsets xml_i="13955" xml_f="13980" txt_i="6309" txt_f="6334">Laboratory determinations</offsets></title><p><offsets xml_i="13991" xml_f="14127" txt_i="6335" txt_f="6471">Glucose levels were measured locally by standard methods, and the measurements were standardized by the central laboratory in Helsinki (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="14158" xml_f="14159" txt_i="6471" txt_f="6472">8</offsets></xref><offsets xml_i="14166" xml_f="14299" txt_i="6472" txt_f="6605">). Serum insulin was determined with a radioimmunoassay (Pharmacia, Uppsala, Sweden) that shows 41% cross-reactivity with proinsulin.</offsets></p></sec><sec id="s10"><title><offsets xml_i="14330" xml_f="14342" txt_i="6607" txt_f="6619">Calculations</offsets></title><p><offsets xml_i="14353" xml_f="14635" txt_i="6620" txt_f="6902">Glucose area under the curve (AUC) during the OGTT was calculated using the trapezoidal method. As surrogate indices of the first/early-phase insulin secretion and of peripheral insulin sensitivity, the ratio of total insulin AUC and total glucose AUC during the 0–30 min OGTT (AIGR</offsets><sub><offsets xml_i="14640" xml_f="14644" txt_i="6902" txt_f="6906">0–30</offsets></sub><offsets xml_i="14650" xml_f="14919" txt_i="6906" txt_f="7175">) and the Matsuda index of insulin sensitivity (Matsuda ISI: 10,000/square root of [fasting glucose × fasting insulin × (arithmetic mean of glucose × arithmetic mean insulin both during an OGTT at 0, 30, and 120 min)]) were calculated according to published equations (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="14951" xml_f="14953" txt_i="7175" txt_f="7177">11</offsets></xref><offsets xml_i="14960" xml_f="14961" txt_i="7177" txt_f="7178">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="14993" xml_f="14995" txt_i="7178" txt_f="7180">12</offsets></xref><offsets xml_i="15002" xml_f="15140" txt_i="7180" txt_f="7318">). These indices were chosen based on a previous large population study conducted by our local collaborators in which Matsuda ISI and AIGR</offsets><sub><offsets xml_i="15145" xml_f="15149" txt_i="7318" txt_f="7322">0–30</offsets></sub><offsets xml_i="15155" xml_f="15227" txt_i="7322" txt_f="7394"> were considered the best indices of insulin sensitivity and secretion (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="15259" xml_f="15261" txt_i="7394" txt_f="7396">11</offsets></xref><offsets xml_i="15268" xml_f="15388" txt_i="7396" txt_f="7516">). In addition, a frequently sampled IVGTT was performed in a subsample of the DPS, and the insulin sensitivity index (S</offsets><sub><offsets xml_i="15393" xml_f="15394" txt_i="7516" txt_f="7517">I</offsets></sub><offsets xml_i="15400" xml_f="15492" txt_i="7517" txt_f="7609">) and acute-phase insulin response (AIR) were calculated by the MINMOD Millennium software (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="15523" xml_f="15524" txt_i="7609" txt_f="7610">9</offsets></xref><offsets xml_i="15531" xml_f="15543" txt_i="7610" txt_f="7622">). AIR and S</offsets><sub><offsets xml_i="15548" xml_f="15549" txt_i="7622" txt_f="7623">I</offsets></sub><offsets xml_i="15555" xml_f="15611" txt_i="7623" txt_f="7679"> measured at year 4 were used for validation of the AIGR</offsets><sub><offsets xml_i="15616" xml_f="15620" txt_i="7679" txt_f="7683">0–30</offsets></sub><offsets xml_i="15626" xml_f="15628" txt_i="7683" txt_f="7685"> (</offsets><italic><offsets xml_i="15636" xml_f="15637" txt_i="7685" txt_f="7686">n</offsets></italic><offsets xml_i="15646" xml_f="15670" txt_i="7686" txt_f="7710"> = 53) and Matsuda ISI (</offsets><italic><offsets xml_i="15678" xml_f="15679" txt_i="7710" txt_f="7711">n</offsets></italic><offsets xml_i="15688" xml_f="15733" txt_i="7711" txt_f="7756"> = 47). The Pearson correlation coefficient (</offsets><italic><offsets xml_i="15741" xml_f="15742" txt_i="7756" txt_f="7757">r</offsets></italic><offsets xml_i="15751" xml_f="15760" txt_i="7757" txt_f="7766">) of AIGR</offsets><sub><offsets xml_i="15765" xml_f="15769" txt_i="7766" txt_f="7770">0–30</offsets></sub><offsets xml_i="15775" xml_f="15795" txt_i="7770" txt_f="7790"> with AIR was 0.67 (</offsets><italic><offsets xml_i="15803" xml_f="15804" txt_i="7790" txt_f="7791">P</offsets></italic><offsets xml_i="15813" xml_f="15860" txt_i="7791" txt_f="7835"> &lt; 0.001). Matsuda ISI had a correlation of </offsets><italic><offsets xml_i="15868" xml_f="15869" txt_i="7835" txt_f="7836">r</offsets></italic><offsets xml_i="15878" xml_f="15887" txt_i="7836" txt_f="7845"> = 0.73 (</offsets><italic><offsets xml_i="15895" xml_f="15896" txt_i="7845" txt_f="7846">P</offsets></italic><offsets xml_i="15905" xml_f="15924" txt_i="7846" txt_f="7862"> &lt; 0.001) with S</offsets><sub><offsets xml_i="15929" xml_f="15930" txt_i="7862" txt_f="7863">I</offsets></sub><offsets xml_i="15936" xml_f="16006" txt_i="7863" txt_f="7933">. We also calculated Matsuda ISI according to the latest publication (</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="16038" xml_f="16040" txt_i="7933" txt_f="7935">13</offsets></xref><offsets xml_i="16047" xml_f="16194" txt_i="7935" txt_f="8082">) to assess insulin sensitivity at baseline without using the 30-min glucose and insulin values. Its correlation coefficient was also significant (</offsets><italic><offsets xml_i="16202" xml_f="16203" txt_i="8082" txt_f="8083">r</offsets></italic><offsets xml_i="16212" xml_f="16221" txt_i="8083" txt_f="8092"> = 0.74, </offsets><italic><offsets xml_i="16229" xml_f="16230" txt_i="8092" txt_f="8093">P</offsets></italic><offsets xml_i="16239" xml_f="16260" txt_i="8093" txt_f="8111"> &lt; 0.001) versus S</offsets><sub><offsets xml_i="16265" xml_f="16266" txt_i="8111" txt_f="8112">I</offsets></sub><offsets xml_i="16272" xml_f="16358" txt_i="8112" txt_f="8198"> in IVGTT. Both Matsuda ISIs were strongly correlated at all 4-year follow-up visits (</offsets><italic><offsets xml_i="16366" xml_f="16367" txt_i="8198" txt_f="8199">r</offsets></italic><offsets xml_i="16376" xml_f="16400" txt_i="8199" txt_f="8223"> between 0.94 and 0.95, </offsets><italic><offsets xml_i="16408" xml_f="16409" txt_i="8223" txt_f="8224">P</offsets></italic><offsets xml_i="16418" xml_f="16439" txt_i="8224" txt_f="8242"> &lt; 0.001 for all).</offsets></p><p><offsets xml_i="16446" xml_f="16598" txt_i="8243" txt_f="8395">Because of the known nonlinear relationship between insulin secretion and insulin sensitivity, we also adjusted, by regression analysis, the log of AIGR</offsets><sub><offsets xml_i="16603" xml_f="16607" txt_i="8395" txt_f="8399">0–30</offsets></sub><offsets xml_i="16613" xml_f="16736" txt_i="8399" txt_f="8522"> by the log of the Matsuda ISI at each year of the study to obtain insulin secretion independently of insulin sensitivity (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="16767" xml_f="16768" txt_i="8522" txt_f="8523">3</offsets></xref><offsets xml_i="16775" xml_f="16776" txt_i="8523" txt_f="8524">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="16807" xml_f="16808" txt_i="8524" txt_f="8525">4</offsets></xref><offsets xml_i="16815" xml_f="16816" txt_i="8525" txt_f="8526">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="16848" xml_f="16850" txt_i="8526" txt_f="8528">14</offsets></xref><offsets xml_i="16857" xml_f="16858" txt_i="8528" txt_f="8529">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="16890" xml_f="16892" txt_i="8529" txt_f="8531">15</offsets></xref><offsets xml_i="16899" xml_f="16939" txt_i="8531" txt_f="8571">). We then transformed the adjusted AIGR</offsets><sub><offsets xml_i="16944" xml_f="16948" txt_i="8571" txt_f="8575">0–30</offsets></sub><offsets xml_i="16954" xml_f="17009" txt_i="8575" txt_f="8630"> back into untransformed values by taking the antilog (</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="17041" xml_f="17043" txt_i="8630" txt_f="8632">14</offsets></xref><offsets xml_i="17050" xml_f="17087" txt_i="8632" txt_f="8669">) to obtain Matsuda ISI-adjusted AIGR</offsets><sub><offsets xml_i="17092" xml_f="17096" txt_i="8669" txt_f="8673">0–30</offsets></sub><offsets xml_i="17102" xml_f="17121" txt_i="8673" txt_f="8692"> (ISI-adjusted AIGR</offsets><sub><offsets xml_i="17126" xml_f="17130" txt_i="8692" txt_f="8696">0–30</offsets></sub><offsets xml_i="17136" xml_f="17156" txt_i="8696" txt_f="8716">). ISI-adjusted AIGR</offsets><sub><offsets xml_i="17161" xml_f="17165" txt_i="8716" txt_f="8720">0–30</offsets></sub><offsets xml_i="17171" xml_f="17202" txt_i="8720" txt_f="8751"> was strongly correlated with S</offsets><sub><offsets xml_i="17207" xml_f="17208" txt_i="8751" txt_f="8752">I</offsets></sub><offsets xml_i="17214" xml_f="17229" txt_i="8752" txt_f="8767">-adjusted AIR (</offsets><italic><offsets xml_i="17237" xml_f="17238" txt_i="8767" txt_f="8768">r</offsets></italic><sub><offsets xml_i="17252" xml_f="17253" txt_i="8768" txt_f="8769">s</offsets></sub><offsets xml_i="17259" xml_f="17268" txt_i="8769" txt_f="8778"> = 0.63, </offsets><italic><offsets xml_i="17276" xml_f="17277" txt_i="8778" txt_f="8779">P</offsets></italic><offsets xml_i="17286" xml_f="17424" txt_i="8779" txt_f="8914"> &lt; 0.001). The outcome variables were averaged from the available yearly measurements of each participant during the 4-year follow-up (</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="17456" xml_f="17458" txt_i="8914" txt_f="8916">16</offsets></xref><offsets xml_i="17465" xml_f="17620" txt_i="8916" txt_f="9071">). For those individuals developing diabetes during the first 4 years, the measurements at the time of conversion to diabetes and thereafter were excluded.</offsets></p></sec><sec id="s11"><title><offsets xml_i="17651" xml_f="17671" txt_i="9073" txt_f="9093">Statistical analyses</offsets></title><p><offsets xml_i="17682" xml_f="18704" txt_i="9094" txt_f="10116">Variables with a non-normal right-skewed distribution were log transformed for statistical analyses and given as geometric mean with a 95% CI. To test the association of the BMI and Matsuda ISI with insulin secretion at the 4-year follow-up and to test whether there was a group effect, univariate general linear models adjusted for age and sex were constructed. The association of insulin secretion and insulin sensitivity during the first 4 years of follow-up with the risk of incident diabetes during a mean of 6 years of follow-up was assessed by Cox proportional hazards regression models adjusted for age, sex, and study group (intervention or control). For those participants who developed diabetes during the first 4 years, the measurements taken at the year of diagnosis were excluded. Univariate general linear modeling was used for comparisons between progressor and nonprogressors to type 2 diabetes during a mean of 6 years of follow-up for the main variables measured during the 4-year follow-up. A value of </offsets><italic><offsets xml_i="18712" xml_f="18713" txt_i="10116" txt_f="10117">P</offsets></italic><offsets xml_i="18722" xml_f="18849" txt_i="10117" txt_f="10241"> &lt; 0.05 was considered statistically significant. Analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL).</offsets></p></sec></sec><sec id="s12"><title><offsets xml_i="18886" xml_f="18893" txt_i="10244" txt_f="10251">RESULTS</offsets></title><sec id="s13"><title><offsets xml_i="18922" xml_f="18951" txt_i="10252" txt_f="10281">Participants’ characteristics</offsets></title><p><offsets xml_i="18962" xml_f="19136" txt_i="10282" txt_f="10456">Individuals in the intervention and control groups included in this analysis had similar body weight, BMI, age, sex distribution, and glucose and insulin levels at baseline (</offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1"><offsets xml_i="19253" xml_f="19274" txt_i="10456" txt_f="10477">Supplementary Table 1</offsets></ext-link><offsets xml_i="19285" xml_f="19460" txt_i="10477" txt_f="10652">). The decrease in fasting and 2-h glucose, body weight, and BMI were already larger in the intervention group than in the control group after the first year of intervention (</offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1"><offsets xml_i="19577" xml_f="19598" txt_i="10652" txt_f="10673">Supplementary Table 2</offsets></ext-link><offsets xml_i="19609" xml_f="19685" txt_i="10673" txt_f="10749">) and were in line with the results reported for the entire DPS population (</offsets><italic><offsets xml_i="19693" xml_f="19694" txt_i="10749" txt_f="10750">n</offsets></italic><offsets xml_i="19703" xml_f="19712" txt_i="10750" txt_f="10759"> = 522) (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="19743" xml_f="19744" txt_i="10759" txt_f="10760">8</offsets></xref><offsets xml_i="19751" xml_f="19752" txt_i="10760" txt_f="10761">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="19784" xml_f="19786" txt_i="10761" txt_f="10763">10</offsets></xref><offsets xml_i="19793" xml_f="19887" txt_i="10763" txt_f="10857">). Insulin sensitivity tended to increase more in the intervention than in the control group (</offsets><italic><offsets xml_i="19895" xml_f="19896" txt_i="10857" txt_f="10858">P</offsets></italic><offsets xml_i="19905" xml_f="20223" txt_i="10858" txt_f="11176"> = 0.07). When divided by the median cutoff point for the change in Matsuda ISI (0.69), the proportion of participants in the higher (mean change, 2.13) and in the lower (−0.41) ranges was significantly different between the intervention (58% and 42%, respectively) and the control (41% and 59%, respectively) groups (</offsets><italic><offsets xml_i="20231" xml_f="20232" txt_i="11176" txt_f="11177">P</offsets></italic><offsets xml_i="20241" xml_f="20251" txt_i="11177" txt_f="11187"> = 0.002).</offsets></p></sec><sec id="s14"><title><offsets xml_i="20282" xml_f="20365" txt_i="11189" txt_f="11272">Fasting and postload glucose and insulin values and BMI during the 4-year follow-up</offsets></title><p><offsets xml_i="20376" xml_f="20500" txt_i="11273" txt_f="11397">Overall, belonging to the intervention group was associated with a better glucose and insulin profile during the follow-up (</offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1"><offsets xml_i="20617" xml_f="20638" txt_i="11397" txt_f="11418">Supplementary Table 3</offsets></ext-link><offsets xml_i="20649" xml_f="20834" txt_i="11418" txt_f="11603">). Participants in the intervention group had lower body weight and BMI during the follow-up than those in the control group, but the difference between the groups was not significant (</offsets><italic><offsets xml_i="20842" xml_f="20843" txt_i="11603" txt_f="11604">P</offsets></italic><offsets xml_i="20852" xml_f="20864" txt_i="11604" txt_f="11616"> = 0.18 and </offsets><italic><offsets xml_i="20872" xml_f="20873" txt_i="11616" txt_f="11617">P</offsets></italic><offsets xml_i="20882" xml_f="20905" txt_i="11617" txt_f="11640"> = 0.25, respectively).</offsets></p></sec><sec id="s15"><title><offsets xml_i="20936" xml_f="21041" txt_i="11642" txt_f="11747">Effect of lifestyle intervention on insulin secretion and insulin sensitivity during the 4-year follow-up</offsets></title><p><offsets xml_i="21052" xml_f="21150" txt_i="11748" txt_f="11846">During the follow-up, although the average value (geometric mean [95% CI]) for the unadjusted AIGR</offsets><sub><offsets xml_i="21155" xml_f="21159" txt_i="11846" txt_f="11850">0–30</offsets></sub><offsets xml_i="21165" xml_f="21271" txt_i="11850" txt_f="11956"> tended to be lower in the intervention than in the control group (30.9 [28.7–33.0] vs. 33.0 [30.8–35.3], </offsets><italic><offsets xml_i="21279" xml_f="21280" txt_i="11956" txt_f="11957">P</offsets></italic><offsets xml_i="21289" xml_f="21440" txt_i="11957" txt_f="12108"> = 0.08), the average Matsuda ISI was significantly higher in the intervention group than in the control group (4.24 [3.99–4.49] vs. 3.85 [3.60–4.11], </offsets><italic><offsets xml_i="21448" xml_f="21449" txt_i="12108" txt_f="12109">P</offsets></italic><offsets xml_i="21458" xml_f="21494" txt_i="12109" txt_f="12145"> = 0.02). However, ISI-adjusted AIGR</offsets><sub><offsets xml_i="21499" xml_f="21503" txt_i="12145" txt_f="12149">0–30</offsets></sub><offsets xml_i="21509" xml_f="21593" txt_i="12149" txt_f="12233"> was not different between the study groups (29.2 [27.9–30.5] vs. 29.5 [28.1–30.9], </offsets><italic><offsets xml_i="21601" xml_f="21602" txt_i="12233" txt_f="12234">P</offsets></italic><offsets xml_i="21611" xml_f="21620" txt_i="12234" txt_f="12243"> = 0.82).</offsets></p></sec><sec id="s16"><title><offsets xml_i="21651" xml_f="21805" txt_i="12245" txt_f="12399">Associations of BMI and insulin sensitivity with early-phase insulin secretion during the 4-year follow-up in the combined intervention and control groups</offsets></title><p><offsets xml_i="21816" xml_f="21876" txt_i="12400" txt_f="12460">In different models, BMI was directly associated (β = 0.27; </offsets><italic><offsets xml_i="21884" xml_f="21885" txt_i="12460" txt_f="12461">P</offsets></italic><offsets xml_i="21894" xml_f="21948" txt_i="12461" txt_f="12512"> &lt; 0.001) and Matsuda ISI was strongly (β = −0.71; </offsets><italic><offsets xml_i="21956" xml_f="21957" txt_i="12512" txt_f="12513">P</offsets></italic><offsets xml_i="21966" xml_f="22009" txt_i="12513" txt_f="12553"> &lt; 0.001) inversely associated with AIGR</offsets><sub><offsets xml_i="22014" xml_f="22018" txt_i="12553" txt_f="12557">0–30</offsets></sub><offsets xml_i="22024" xml_f="22091" txt_i="12557" txt_f="12624"> during the follow-up, and both attenuated the group effect on AIGR</offsets><sub><offsets xml_i="22096" xml_f="22100" txt_i="12624" txt_f="12628">0–30</offsets></sub><offsets xml_i="22106" xml_f="22108" txt_i="12628" txt_f="12630"> (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="22140" xml_f="22147" txt_i="12630" txt_f="12637">Table 1</offsets></xref><offsets xml_i="22154" xml_f="22208" txt_i="12637" txt_f="12691">). BMI was inversely associated with ISI-adjusted AIGR</offsets><sub><offsets xml_i="22213" xml_f="22217" txt_i="12691" txt_f="12695">0–30</offsets></sub><offsets xml_i="22223" xml_f="22255" txt_i="12695" txt_f="12727"> during this period (β = −0.12; </offsets><italic><offsets xml_i="22263" xml_f="22264" txt_i="12727" txt_f="12728">P</offsets></italic><offsets xml_i="22273" xml_f="22414" txt_i="12728" txt_f="12869"> = 0.03). In models where Matsuda ISI was placed as the dependent variable, higher BMI was inversely associated with Matsuda ISI (β = −0.49; </offsets><italic><offsets xml_i="22422" xml_f="22423" txt_i="12869" txt_f="12870">P</offsets></italic><offsets xml_i="22432" xml_f="22552" txt_i="12870" txt_f="12987"> &lt; 0.001) independently of study group, and BMI also attenuated the effect of lifestyle intervention on Matsuda ISI (</offsets><italic><offsets xml_i="22560" xml_f="22561" txt_i="12987" txt_f="12988">P</offsets></italic><offsets xml_i="22570" xml_f="22600" txt_i="12988" txt_f="13018"> = 0.07 for the group effect).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="22648" xml_f="22655" txt_i="13019" txt_f="13026">Table 1</offsets></label><caption><p><offsets xml_i="22675" xml_f="22720" txt_i="13026" txt_f="13071">Associations of BMI and Matsuda ISI with AIGR</offsets><sub><offsets xml_i="22725" xml_f="22729" txt_i="13071" txt_f="13075">0–30</offsets></sub><offsets xml_i="22735" xml_f="22762" txt_i="13075" txt_f="13102"> and with ISI-adjusted AIGR</offsets><sub><offsets xml_i="22767" xml_f="22771" txt_i="13102" txt_f="13106">0–30</offsets></sub><offsets xml_i="22777" xml_f="22842" txt_i="13106" txt_f="13171"> during the 4-year follow-up in participants from the Finnish DPS</offsets></p></caption><graphic xlink:href="211tbl1"></graphic></table-wrap></sec><sec id="s17"><title><offsets xml_i="22936" xml_f="23085" txt_i="13173" txt_f="13322">Impact of changes in BMI and insulin sensitivity after the first year of intervention on the insulin secretion during the subsequent 4-year follow-up</offsets></title><p><offsets xml_i="23096" xml_f="23267" txt_i="13323" txt_f="13494">A greater decrease in BMI or a greater increase in Matsuda ISI after the first year of intervention (the most intensive period of the study) was associated with lower AIGR</offsets><sub><offsets xml_i="23272" xml_f="23276" txt_i="13494" txt_f="13498">0–30</offsets></sub><offsets xml_i="23282" xml_f="23312" txt_i="13498" txt_f="13528"> at the subsequent follow-up (</offsets><italic><offsets xml_i="23320" xml_f="23321" txt_i="13528" txt_f="13529">P</offsets></italic><offsets xml_i="23330" xml_f="23388" txt_i="13529" txt_f="13584"> &lt; 0.001) and again attenuated the group effect on AIGR</offsets><sub><offsets xml_i="23393" xml_f="23397" txt_i="13584" txt_f="13588">0–30</offsets></sub><offsets xml_i="23403" xml_f="23426" txt_i="13588" txt_f="13611"> during the follow-up (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="23458" xml_f="23465" txt_i="13611" txt_f="13618">Table 1</offsets></xref><offsets xml_i="23472" xml_f="23560" txt_i="13618" txt_f="13706">). A greater decrease in BMI during this period had a weaker effect on ISI-adjusted AIGR</offsets><sub><offsets xml_i="23565" xml_f="23569" txt_i="13706" txt_f="13710">0–30</offsets></sub><offsets xml_i="23575" xml_f="23577" txt_i="13710" txt_f="13712"> (</offsets><italic><offsets xml_i="23585" xml_f="23586" txt_i="13712" txt_f="13713">P</offsets></italic><offsets xml_i="23595" xml_f="23616" txt_i="13713" txt_f="13734"> = 0.03) than in AIGR</offsets><sub><offsets xml_i="23621" xml_f="23625" txt_i="13734" txt_f="13738">0–30</offsets></sub><offsets xml_i="23631" xml_f="23804" txt_i="13738" txt_f="13911">. In similar models, being in the group of participants with a greater increase in Matsuda ISI based on the median cutoff (0.69) was associated with higher ISI-adjusted AIGR</offsets><sub><offsets xml_i="23809" xml_f="23813" txt_i="13911" txt_f="13915">0–30</offsets></sub><offsets xml_i="23819" xml_f="23900" txt_i="13915" txt_f="13996"> during the follow-up than those with less improvement in Matsuda ISI (β = 0.29, </offsets><italic><offsets xml_i="23908" xml_f="23909" txt_i="13996" txt_f="13997">P</offsets></italic><offsets xml_i="23918" xml_f="23928" txt_i="13997" txt_f="14007"> = 0.002).</offsets></p></sec><sec id="s18"><title><offsets xml_i="23959" xml_f="24085" txt_i="14009" txt_f="14135">Early-phase insulin secretion and glucose response in the combined intervention and control groups during the 4-year follow-up</offsets></title><p><offsets xml_i="24096" xml_f="24151" txt_i="14136" txt_f="14191">During the follow-up, Matsuda ISI and ISI-adjusted AIGR</offsets><sub><offsets xml_i="24156" xml_f="24160" txt_i="14191" txt_f="14195">0–30</offsets></sub><offsets xml_i="24166" xml_f="24271" txt_i="14195" txt_f="14300"> were independently associated with lower concentrations of fasting glucose, 2-h glucose, and glucose AUC</offsets><sub><offsets xml_i="24276" xml_f="24281" txt_i="14300" txt_f="14305">0–120</offsets></sub><offsets xml_i="24287" xml_f="24338" txt_i="14305" txt_f="14356"> in models adjusted for age, sex, and study group (</offsets><italic><offsets xml_i="24346" xml_f="24347" txt_i="14356" txt_f="14357">P</offsets></italic><offsets xml_i="24356" xml_f="24369" txt_i="14357" txt_f="14367"> &lt; 0.001, </offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1"><offsets xml_i="24486" xml_f="24507" txt_i="14367" txt_f="14388">Supplementary Table 4</offsets></ext-link><offsets xml_i="24518" xml_f="24520" txt_i="14388" txt_f="14390">).</offsets></p></sec><sec id="s19"><title><offsets xml_i="24551" xml_f="24632" txt_i="14392" txt_f="14473">Early-phase insulin secretion and insulin sensitivity and development of diabetes</offsets></title><p><offsets xml_i="24643" xml_f="25028" txt_i="14474" txt_f="14859">During a mean follow-up of 6 years (range 1–10), the number of diabetes cases was 71 in the control and 60 in the intervention groups. After taking into account the effects of the study group, age, and sex, participants who progressed from IGT to diabetes compared with those who did not progress to diabetes during the mean 6-year follow-up had lower Matsuda ISI and ISI-adjusted AIGR</offsets><sub><offsets xml_i="25033" xml_f="25037" txt_i="14859" txt_f="14863">0–30</offsets></sub><offsets xml_i="25043" xml_f="25113" txt_i="14863" txt_f="14933"> and higher BMI on average during the 4-year follow-up study, but AIGR</offsets><sub><offsets xml_i="25118" xml_f="25122" txt_i="14933" txt_f="14937">0–30</offsets></sub><offsets xml_i="25128" xml_f="25159" txt_i="14937" txt_f="14968"> was identical in both groups (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="25191" xml_f="25198" txt_i="14968" txt_f="14975">Table 2</offsets></xref><offsets xml_i="25205" xml_f="25324" txt_i="14975" txt_f="15094">). Participants who developed diabetes also reduced less their body weight and BMI during the first year of the trial (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="25356" xml_f="25363" txt_i="15094" txt_f="15101">Table 2</offsets></xref><offsets xml_i="25370" xml_f="25372" txt_i="15101" txt_f="15103">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="25420" xml_f="25427" txt_i="15104" txt_f="15111">Table 2</offsets></label><caption><p><offsets xml_i="25447" xml_f="25456" txt_i="15111" txt_f="15120">BMI, AIGR</offsets><sub><offsets xml_i="25461" xml_f="25465" txt_i="15120" txt_f="15124">0–30</offsets></sub><offsets xml_i="25471" xml_f="25507" txt_i="15124" txt_f="15160">, Matsuda ISI, and ISI-adjusted AIGR</offsets><sub><offsets xml_i="25512" xml_f="25516" txt_i="15160" txt_f="15164">0–30</offsets></sub><offsets xml_i="25522" xml_f="25754" txt_i="15164" txt_f="15396"> during the 4-year follow-up and body weight and BMI change during the first year of the intervention study in participants of the Finnish DPS who did or did not progress from IGT to type 2 diabetes after a mean follow-up of 6 years</offsets></p></caption><graphic xlink:href="211tbl2"></graphic></table-wrap><p><offsets xml_i="25824" xml_f="25901" txt_i="15397" txt_f="15474">Cox regression analyses showed that average Matsuda ISI and ISI-adjusted AIGR</offsets><sub><offsets xml_i="25906" xml_f="25910" txt_i="15474" txt_f="15478">0–30</offsets></sub><offsets xml_i="25916" xml_f="26029" txt_i="15478" txt_f="15591"> during the follow-up were inversely associated with the incidence of diabetes during the mean 6-year follow-up (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="26061" xml_f="26068" txt_i="15591" txt_f="15598">Table 3</offsets></xref><offsets xml_i="26075" xml_f="26100" txt_i="15598" txt_f="15623">). Although average AIGR </offsets><sub><offsets xml_i="26105" xml_f="26109" txt_i="15623" txt_f="15627">0–30</offsets></sub><offsets xml_i="26115" xml_f="26448" txt_i="15627" txt_f="15960"> during the 4-year follow-up alone did not predict diabetes, when Matsuda ISI was included in the model, lower insulin secretion and insulin sensitivity both predicted progression to diabetes. Higher BMI during the follow-up or lower BMI change during the first year of the lifestyle intervention study alone or independently of AIGR</offsets><sub><offsets xml_i="26453" xml_f="26457" txt_i="15960" txt_f="15964">0–30</offsets></sub><offsets xml_i="26463" xml_f="26564" txt_i="15964" txt_f="16065"> predicted diabetes. This association was no longer significant when Matsuda ISI or ISI-adjusted AIGR</offsets><sub><offsets xml_i="26569" xml_f="26573" txt_i="16065" txt_f="16069">0–30</offsets></sub><offsets xml_i="26579" xml_f="26606" txt_i="16069" txt_f="16096"> was included in the model.</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="26654" xml_f="26661" txt_i="16097" txt_f="16104">Table 3</offsets></label><caption><p><offsets xml_i="26681" xml_f="26806" txt_i="16104" txt_f="16229">Hazard ratios for the risk of developing type 2 diabetes during a mean of 6-year follow-up according to a 1-SD change in AIGR</offsets><sub><offsets xml_i="26811" xml_f="26815" txt_i="16229" txt_f="16233">0–30</offsets></sub><offsets xml_i="26821" xml_f="26857" txt_i="16233" txt_f="16269">, Matsuda ISI, and ISI-adjusted AIGR</offsets><sub><offsets xml_i="26862" xml_f="26866" txt_i="16269" txt_f="16273">0–30</offsets></sub><offsets xml_i="26872" xml_f="26933" txt_i="16273" txt_f="16334"> at the 4-year follow-up in participants from the Finnish DPS</offsets></p></caption><graphic xlink:href="211tbl3"></graphic></table-wrap><p><offsets xml_i="27003" xml_f="27130" txt_i="16335" txt_f="16462">Of note, in similar models assessing the regression from IGT to normal glucose tolerance (NGT) during a mean 6-year follow-up (</offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1"><offsets xml_i="27247" xml_f="27268" txt_i="16462" txt_f="16483">Supplementary Table 5</offsets></ext-link><offsets xml_i="27279" xml_f="27318" txt_i="16483" txt_f="16522">), a 1-SD increase in ISI-adjusted AIGR</offsets><sub><offsets xml_i="27323" xml_f="27327" txt_i="16522" txt_f="16526">0–30</offsets></sub><offsets xml_i="27333" xml_f="27404" txt_i="16526" txt_f="16597"> was associated with a 1.3 increase in the regression from IGT to NGT (</offsets><italic><offsets xml_i="27412" xml_f="27413" txt_i="16597" txt_f="16598">P</offsets></italic><offsets xml_i="27422" xml_f="27437" txt_i="16598" txt_f="16613"> = 0.002). AIGR</offsets><sub><offsets xml_i="27442" xml_f="27446" txt_i="16613" txt_f="16617">0–30</offsets></sub><offsets xml_i="27452" xml_f="27532" txt_i="16617" txt_f="16697"> and Matsuda ISI alone were not associated with the regression from IGT to NGT (</offsets><italic><offsets xml_i="27540" xml_f="27541" txt_i="16697" txt_f="16698">P</offsets></italic><offsets xml_i="27550" xml_f="27562" txt_i="16698" txt_f="16710"> = 0.29 and </offsets><italic><offsets xml_i="27570" xml_f="27571" txt_i="16710" txt_f="16711">P</offsets></italic><offsets xml_i="27580" xml_f="27673" txt_i="16711" txt_f="16804"> = 0.14, respectively), but when they were entered in the same model, a 1-SD increase in AIGR</offsets><sub><offsets xml_i="27678" xml_f="27682" txt_i="16804" txt_f="16808">0–30</offsets></sub><offsets xml_i="27688" xml_f="27775" txt_i="16808" txt_f="16895"> and Matsuda ISI was associated with a 1.5 increase in the regression from IGT to NGT (</offsets><italic><offsets xml_i="27783" xml_f="27784" txt_i="16895" txt_f="16896">P</offsets></italic><offsets xml_i="27793" xml_f="27830" txt_i="16896" txt_f="16933"> = 0.001), independently also of BMI.</offsets></p></sec></sec><sec id="s20"><title><offsets xml_i="27867" xml_f="27878" txt_i="16936" txt_f="16947">CONCLUSIONS</offsets></title><p><offsets xml_i="27889" xml_f="28205" txt_i="16948" txt_f="17264">Nonpharmacologic lifestyle intervention in high-risk individuals prevented or at least postponed the onset of type 2 diabetes in the Finnish DPS. Participants in the intervention group showed greater reductions in fasting and postchallenge glucose levels and in body weight compared with those in the control group (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="28236" xml_f="28237" txt_i="17264" txt_f="17265">8</offsets></xref><offsets xml_i="28244" xml_f="28245" txt_i="17265" txt_f="17266">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="28277" xml_f="28279" txt_i="17266" txt_f="17268">10</offsets></xref><offsets xml_i="28286" xml_f="28288" txt_i="17268" txt_f="17270">).</offsets></p><p><offsets xml_i="28295" xml_f="28466" txt_i="17271" txt_f="17442">In the current study, we demonstrated that higher insulin sensitivity estimated as Matsuda ISI and higher insulin sensitivity-adjusted insulin secretion (ISI-adjusted AIGR</offsets><sub><offsets xml_i="28471" xml_f="28475" txt_i="17442" txt_f="17446">0–30</offsets></sub><offsets xml_i="28481" xml_f="28680" txt_i="17446" txt_f="17645">) during the 4-year follow-up study were both associated with lower diabetes incidence during a mean follow-up of 6 years. Regression to NGT was more strongly associated with higher ISI-adjusted AIGR</offsets><sub><offsets xml_i="28685" xml_f="28689" txt_i="17645" txt_f="17649">0–30</offsets></sub><offsets xml_i="28695" xml_f="28888" txt_i="17649" txt_f="17842"> than insulin sensitivity. Individuals who developed type 2 diabetes reduced less BMI during the first year of the intervention, were more obese, and had lower Matsuda ISI and ISI-adjusted AIGR</offsets><sub><offsets xml_i="28893" xml_f="28897" txt_i="17842" txt_f="17846">0–30</offsets></sub><offsets xml_i="28903" xml_f="28985" txt_i="17846" txt_f="17928"> values during the study than the individuals who did not develop type 2 diabetes.</offsets></p><p><offsets xml_i="28992" xml_f="29010" txt_i="17929" txt_f="17947">We found that AIGR</offsets><sub><offsets xml_i="29015" xml_f="29019" txt_i="17947" txt_f="17951">0–30</offsets></sub><offsets xml_i="29025" xml_f="29218" txt_i="17951" txt_f="18144"> per se did not predict diabetes during the mean 6-year follow-up, unless Matsuda ISI contribution was taken into consideration in the models. In contrast, low Matsuda ISI and ISI-adjusted AIGR</offsets><sub><offsets xml_i="29223" xml_f="29227" txt_i="18144" txt_f="18148">0–30</offsets></sub><offsets xml_i="29233" xml_f="29474" txt_i="18148" txt_f="18389"> were both associated with a higher risk of developing diabetes, independently of BMI. Previous prospective studies have shown that insulin resistance and impaired early-phase insulin secretion predicted the conversion from IGT to diabetes (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="29505" xml_f="29506" txt_i="18389" txt_f="18390">2</offsets></xref><offsets xml_i="29513" xml_f="29514" txt_i="18390" txt_f="18391">–</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="29545" xml_f="29546" txt_i="18391" txt_f="18392">5</offsets></xref><offsets xml_i="29553" xml_f="29554" txt_i="18392" txt_f="18393">,</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="29586" xml_f="29588" txt_i="18393" txt_f="18395">17</offsets></xref><offsets xml_i="29595" xml_f="29596" txt_i="18395" txt_f="18396">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="29628" xml_f="29630" txt_i="18396" txt_f="18398">18</offsets></xref><offsets xml_i="29637" xml_f="29835" txt_i="18398" txt_f="18596">). Moreover, in insulin-resistant states, improvement of insulin resistance protected from diabetes and was associated with lower endogenous insulin requirement and preservation of β-cell function (</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="29867" xml_f="29869" txt_i="18596" txt_f="18598">19</offsets></xref><offsets xml_i="29876" xml_f="30340" txt_i="18598" txt_f="19062">). Therefore, some improvement in insulin secretion adjusted for insulin sensitivity seems to be possible in the IGT phase, resulting in better β-cell function and possibly lowering the risk of developing diabetes. Altogether, these findings clearly demonstrate the importance of insulin secretion in the development of type 2 diabetes and that the effect of insulin sensitivity on insulin secretion needs to be taken into account due to their complex interaction.</offsets></p><p><offsets xml_i="30347" xml_f="30584" txt_i="19063" txt_f="19300">In line with published observations, we observed that insulin sensitivity, which was higher in the intervention than in the control group during the 4-year follow-up, was inversely associated with the risk of developing type 2 diabetes (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="30615" xml_f="30616" txt_i="19300" txt_f="19301">3</offsets></xref><offsets xml_i="30623" xml_f="30624" txt_i="19301" txt_f="19302">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="30655" xml_f="30656" txt_i="19302" txt_f="19303">5</offsets></xref><offsets xml_i="30663" xml_f="30664" txt_i="19303" txt_f="19304">,</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="30696" xml_f="30698" txt_i="19304" txt_f="19306">17</offsets></xref><offsets xml_i="30705" xml_f="31000" txt_i="19306" txt_f="19601">) and also inversely associated with BMI during this same interval. In previous findings from a subsample of individuals participating in the DPS, the improvement in insulin sensitivity between baseline and the fourth year of the study was strongly correlated with the magnitude of weight loss (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="31031" xml_f="31032" txt_i="19601" txt_f="19602">9</offsets></xref><offsets xml_i="31039" xml_f="31260" txt_i="19602" txt_f="19823">). These findings were independent of randomization group, and the associations found could be partly explained, for example, by a possible decrease in nonesterified fatty acid release that accompanies loss of body mass (</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="31292" xml_f="31294" txt_i="19823" txt_f="19825">20</offsets></xref><offsets xml_i="31301" xml_f="31302" txt_i="19825" txt_f="19826">,</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="31334" xml_f="31336" txt_i="19826" txt_f="19828">21</offsets></xref><offsets xml_i="31343" xml_f="31345" txt_i="19828" txt_f="19830">).</offsets></p><p><offsets xml_i="31352" xml_f="31404" txt_i="19831" txt_f="19883">Although at first glance paradoxical, the lower AIGR</offsets><sub><offsets xml_i="31409" xml_f="31413" txt_i="19883" txt_f="19887">0–30</offsets></sub><offsets xml_i="31419" xml_f="31906" txt_i="19887" txt_f="20374"> observed in the lifestyle intervention group can be explained by the improvement in Matsuda ISI, which remained higher during the follow-up in this group, and reductions in body weight and BMI in the intervention arm during the first year of the study compared with the control group. Our study, along with other studies but with shorter follow-up duration, shows that a lower BMI and better insulin sensitivity are associated with a decrease in the demand of insulin in obese, insulin-</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="31938" xml_f="31940" txt_i="20374" txt_f="20376">22</offsets></xref><offsets xml_i="31947" xml_f="31948" txt_i="20376" txt_f="20377">–</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="31980" xml_f="31982" txt_i="20377" txt_f="20379">24</offsets></xref><offsets xml_i="31989" xml_f="31991" txt_i="20379" txt_f="20381">).</offsets></p><p><offsets xml_i="31998" xml_f="32103" txt_i="20382" txt_f="20487">We could not find any difference between the intervention and control groups concerning ISI-adjusted AIGR</offsets><sub><offsets xml_i="32108" xml_f="32112" txt_i="20487" txt_f="20491">0–30</offsets></sub><offsets xml_i="32118" xml_f="32364" txt_i="20491" txt_f="20737"> that could indicate a direct beneficial effect of lifestyle intervention on β-cell function. Excluding data from the year diabetes was diagnosed may have underestimated the effect of lifestyle intervention. Nevertheless, higher ISI-adjusted AIGR</offsets><sub><offsets xml_i="32369" xml_f="32373" txt_i="20737" txt_f="20741">0–30</offsets></sub><offsets xml_i="32379" xml_f="32725" txt_i="20741" txt_f="21087"> during the follow-up was associated with a lower risk of developing diabetes and a higher chance of regressing from IGT to NGT. Moreover, participants who had higher increase in Matsuda ISI during the most intensive period of the intervention trial, and who mostly belonged to the intervention group by study design, had higher ISI-adjusted AIGR</offsets><sub><offsets xml_i="32730" xml_f="32734" txt_i="21087" txt_f="21091">0–30</offsets></sub><offsets xml_i="32740" xml_f="33124" txt_i="21091" txt_f="21475"> during the follow-up. Therefore, weight loss achieved with the lifestyle intervention may be a mediating factor on preserving β-cell function by improving insulin sensitivity and perhaps by avoiding lipotoxicity resulting for example, from ectopic fat accumulation, higher release of nonesterified fatty acid, and activation of inflammatory cascades, all factors related to obesity (</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="33156" xml_f="33158" txt_i="21475" txt_f="21477">20</offsets></xref><offsets xml_i="33165" xml_f="33166" txt_i="21477" txt_f="21478">,</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="33198" xml_f="33200" txt_i="21478" txt_f="21480">21</offsets></xref><offsets xml_i="33207" xml_f="33417" txt_i="21480" txt_f="21690">). Overall, our findings emphasize the importance of targeting reduction in BMI to improve insulin sensitivity and preserve insulin secretion capacity to prevent or postpone the conversion from IGT to diabetes.</offsets></p><p><offsets xml_i="33424" xml_f="34263" txt_i="21691" txt_f="22530">A major limitation of our study was that we could not estimate early-phase insulin secretion and sensitivity from OGTT at baseline before the intervention began. Nonetheless, the main clinical and metabolic features related to insulin and glucose metabolism, such as BMI, age, sex proportion, glucose, and insulin parameters did not differ between the intervention and control groups. Therefore, the differences between groups reported in this study are likely to be a reflection of the intervention itself. Of note, diabetes incidence was similarly lower in the original intervention group as in the population included in this study. Insulin sensitivity and insulin secretion were not measured by the hyperinsulinemic-euglycemic clamp or the IVGTT. We did not use the oral glucose minimal model indices for estimating insulin secretion (</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="34295" xml_f="34297" txt_i="22530" txt_f="22532">25</offsets></xref><offsets xml_i="34304" xml_f="34653" txt_i="22532" txt_f="22881">), which also includes the incretin response, because we did not measure C-peptide. However, we used an IVGTT for validation of the indices used in the current study in a subsample of the DPS. In DPS, early-phase insulin secretion (AIR) has high repeatability, which, as the insulin sensitivity-adjusted AIR, was also associated with diabetes risk (</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="34685" xml_f="34687" txt_i="22881" txt_f="22883">16</offsets></xref><offsets xml_i="34694" xml_f="34726" txt_i="22883" txt_f="22915">). In a similar population, AIGR</offsets><sub><offsets xml_i="34731" xml_f="34735" txt_i="22915" txt_f="22919">0–30</offsets></sub><offsets xml_i="34741" xml_f="34829" txt_i="22919" txt_f="23007"> and Matsuda ISI were considered the best indices of insulin sensitivity and secretion (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="34861" xml_f="34863" txt_i="23007" txt_f="23009">11</offsets></xref><offsets xml_i="34870" xml_f="35266" txt_i="23009" txt_f="23405">). The averaged values of measures of obesity, insulin sensitivity, and insulin secretion during the 4-year follow-up were used for the analyses. The main changes in lifestyle and body weight occurred during the first year of the study and were largely maintained thereafter. To decrease the variability of the crude measurements and increase the statistical power, we therefore averaged values (</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="35298" xml_f="35300" txt_i="23405" txt_f="23407">16</offsets></xref><offsets xml_i="35307" xml_f="35309" txt_i="23407" txt_f="23409">).</offsets></p><p><offsets xml_i="35316" xml_f="35581" txt_i="23410" txt_f="23675">Strengths of the current study include the well-characterized and homogenous study population (obese individuals with IGT) and yearly measurements during a relative long period of follow-up of a large and carefully conducted lifestyle intervention study population.</offsets></p><p><offsets xml_i="35588" xml_f="36203" txt_i="23676" txt_f="24291">Our results indicate that the reduction in the risk of developing type 2 diabetes after lifestyle intervention is related to the improvement of insulin sensitivity. The weight loss achieved with the lifestyle intervention, which also improved insulin sensitivity, might have beneficial effects on better preservation of β-cell function. Because weight loss results from joint effects of changes in diet and physical activity and is possibly modified by genetic factors, the interplay between their effects on insulin secretion and risk of developing type 2 diabetes requires further and more detailed investigation.</offsets></p></sec><offsets xml_i="36213" xml_f="36220" txt_i="24293" txt_f="24300">
      </offsets><sec sec-type="supplementary-material"><offsets xml_i="36259" xml_f="36269" txt_i="24300" txt_f="24310">
         </offsets><title><offsets xml_i="36276" xml_f="36298" txt_i="24310" txt_f="24332">Supplementary Material</offsets></title><offsets xml_i="36306" xml_f="36316" txt_i="24333" txt_f="24343">
         </offsets><supplementary-material id="PMC_1" content-type="local-data"><offsets xml_i="36377" xml_f="36390" txt_i="24343" txt_f="24356">
            </offsets><caption><offsets xml_i="36399" xml_f="36415" txt_i="24356" txt_f="24372">
               </offsets><title><offsets xml_i="36422" xml_f="36440" txt_i="24372" txt_f="24390">Supplementary Data</offsets></title><offsets xml_i="36448" xml_f="36461" txt_i="24391" txt_f="24404">
            </offsets></caption><offsets xml_i="36471" xml_f="36484" txt_i="24404" txt_f="24417">
            </offsets><media mimetype="text" mime-subtype="html" xlink:href="supp_35_2_211__index.html"></media><offsets xml_i="36574" xml_f="36587" txt_i="24417" txt_f="24430">
            </offsets><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_dc11-1272v111272_DC111272SupplementaryData.pdf"></media><offsets xml_i="36738" xml_f="36748" txt_i="24430" txt_f="24440">
         </offsets></supplementary-material><offsets xml_i="36773" xml_f="36780" txt_i="24440" txt_f="24447">
      </offsets></sec><offsets xml_i="36786" xml_f="36790" txt_i="24448" txt_f="24452">
   </offsets></body><back><fn-group><fn id="fn1"><p>Clinical trial reg. no. NCT00518167, <ext-link ext-link-type="uri" xlink:href="clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p></fn><fn id="fn2" fn-type="supplementary-material"><p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1272/-/DC1</ext-link>.</p></fn></fn-group><ack><title>Acknowledgments</title><p>This study was supported by the Academy of Finland (117844, 40758, 211497, and 118590 to M.U.; 38387 and 46558 to J.T.; 206310 and 73566 to S.K.-K.; 128315 and 129330 to J.L.; and 131593 to V.D.F.d.M.), the Juho Vainio Foundation (to J.L.), the Novo Nordisk Foundation (to J.L.), the EVO fund of Kuopio University Hospital (5106, 5168, and 5254 to M.U.), and the Ministry of Education of Finland, The Finnish Diabetes Research Foundation, Sigrid Juselius Foundation, North-Savo Finnish Cultural Foundation, and Nordic Centre of Excellence (NCoE) on “Systems biology in controlled dietary interventions and cohort studies” (SYSDIET; project number 070014).</p><p>No potential conflicts of interest relevant to this article were reported.</p><p>V.D.F.d.M. analyzed the data, wrote, reviewed, and edited the manuscript, and is the guarantor of the work. J.L. and S.K.-K. participated in data collection, contributed to discussion, and reviewed and edited the manuscript. J.E. and M.L. contributed to discussion and reviewed and edited the manuscript. P.I.-P. and J.S. participated in data collection and reviewed and edited the manuscript. J.T. is a principal investigator of the DPS, contributed to discussion, and reviewed and edited the manuscript. M.U. is a principal investigator of the DPS, participated in data collection, contributed to discussion, and reviewed and edited the manuscript.</p><p>This study was presented as an oral communication at the 29th International Symposium on Diabetes and Nutrition, Rome, Italy, 30 June–2 July 2011.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group> <article-title>Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus</article-title>. <source>Diabetes</source> <year>2009</year>;<volume>58</volume>:<fpage>773</fpage>–<lpage>795</lpage><pub-id pub-id-type="pmid">19336687</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>SE</given-names></name></person-group> <article-title>The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes</article-title>. <source>Diabetologia</source> <year>2003</year>;<volume>46</volume>:<fpage>3</fpage>–<lpage>19</lpage><pub-id pub-id-type="pmid">12637977</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitabchi</surname><given-names>AE</given-names></name><name><surname>Temprosa</surname><given-names>M</given-names></name><name><surname>Knowler</surname><given-names>WC</given-names></name><etal></etal></person-group>; <collab>Diabetes Prevention Program Research Group</collab> <article-title>Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin</article-title>. <source>Diabetes</source> <year>2005</year>;<volume>54</volume>:<fpage>2404</fpage>–<lpage>2414</lpage><pub-id pub-id-type="pmid">16046308</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Festa</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>D’Agostino</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Wagenknecht</surname><given-names>LE</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name></person-group> <article-title>The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study</article-title>. <source>Diabetes</source> <year>2006</year>;<volume>55</volume>:<fpage>1114</fpage>–<lpage>1120</lpage><pub-id pub-id-type="pmid">16567536</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snehalatha</surname><given-names>C</given-names></name><name><surname>Mary</surname><given-names>S</given-names></name><name><surname>Selvam</surname><given-names>S</given-names></name><etal></etal></person-group> <article-title>Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1)</article-title>. <source>Diabetes Care</source> <year>2009</year>;<volume>32</volume>:<fpage>1796</fpage>–<lpage>1801</lpage><pub-id pub-id-type="pmid">19587369</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowler</surname><given-names>WC</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Fowler</surname><given-names>SE</given-names></name><etal></etal></person-group>; <collab>Diabetes Prevention Program Research Group</collab> <article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title>. <source>N Engl J Med</source> <year>2002</year>;<volume>346</volume>:<fpage>393</fpage>–<lpage>403</lpage><pub-id pub-id-type="pmid">11832527</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>A</given-names></name><name><surname>Snehalatha</surname><given-names>C</given-names></name><name><surname>Mary</surname><given-names>S</given-names></name><name><surname>Mukesh</surname><given-names>B</given-names></name><name><surname>Bhaskar</surname><given-names>AD</given-names></name><name><surname>Vijay</surname><given-names>V</given-names></name></person-group>; <collab>Indian Diabetes Prevention Programme (IDPP)</collab> <article-title>The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)</article-title>. <source>Diabetologia</source> <year>2006</year>;<volume>49</volume>:<fpage>289</fpage>–<lpage>297</lpage><pub-id pub-id-type="pmid">16391903</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Lindström</surname><given-names>J</given-names></name><name><surname>Eriksson</surname><given-names>JG</given-names></name><etal></etal></person-group>; <collab>Finnish Diabetes Prevention Study Group</collab> <article-title>Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</article-title>. <source>N Engl J Med</source> <year>2001</year>;<volume>344</volume>:<fpage>1343</fpage>–<lpage>1350</lpage><pub-id pub-id-type="pmid">11333990</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uusitupa</surname><given-names>M</given-names></name><name><surname>Lindi</surname><given-names>V</given-names></name><name><surname>Louheranta</surname><given-names>A</given-names></name><name><surname>Salopuro</surname><given-names>T</given-names></name><name><surname>Lindström</surname><given-names>J</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name></person-group> <article-title>Long-term improvement in insulin sensitivity by changing lifestyles of persons with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study</article-title>. <source>Diabetes</source> <year>2003</year>;<volume>52</volume>:<fpage>2532</fpage>–<lpage>2538</lpage><pub-id pub-id-type="pmid">14514637</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindström</surname><given-names>J</given-names></name><name><surname>Louheranta</surname><given-names>A</given-names></name><name><surname>Mannelin</surname><given-names>M</given-names></name><etal></etal></person-group>; <collab>Finnish Diabetes Prevention Study Group</collab> <article-title>The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity</article-title>. <source>Diabetes Care</source> <year>2003</year>;<volume>26</volume>:<fpage>3230</fpage>–<lpage>3236</lpage><pub-id pub-id-type="pmid">14633807</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stancáková</surname><given-names>A</given-names></name><name><surname>Javorský</surname><given-names>M</given-names></name><name><surname>Kuulasmaa</surname><given-names>T</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name><name><surname>Kuusisto</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name></person-group> <article-title>Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men</article-title>. <source>Diabetes</source> <year>2009</year>;<volume>58</volume>:<fpage>1212</fpage>–<lpage>1221</lpage><pub-id pub-id-type="pmid">19223598</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group> <article-title>Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp</article-title>. <source>Diabetes Care</source> <year>1999</year>;<volume>22</volume>:<fpage>1462</fpage>–<lpage>1470</lpage><pub-id pub-id-type="pmid">10480510</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name></person-group> <article-title>Reduced time points to calculate the composite index</article-title>. <source>Diabetes Care</source> <year>2010</year>;<volume>33</volume>:<fpage>e93</fpage><pub-id pub-id-type="pmid">20587713</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laaksonen</surname><given-names>DE</given-names></name><name><surname>Niskanen</surname><given-names>L</given-names></name><name><surname>Mykkänen</surname><given-names>H</given-names></name><etal></etal></person-group> <article-title>Long-term repeatability of measures of early insulin secretion derived from an intravenous glucose tolerance test and conversion from impaired glucose tolerance to diabetes</article-title>. <source>Ann Med</source> <year>2008</year>;<volume>40</volume>:<fpage>303</fpage>–<lpage>311</lpage><pub-id pub-id-type="pmid">18428023</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>SE</given-names></name><name><surname>Prigeon</surname><given-names>RL</given-names></name><name><surname>McCulloch</surname><given-names>DK</given-names></name><etal></etal></person-group> <article-title>Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function</article-title>. <source>Diabetes</source> <year>1993</year>;<volume>42</volume>:<fpage>1663</fpage>–<lpage>1672</lpage><pub-id pub-id-type="pmid">8405710</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laaksonen</surname><given-names>DE</given-names></name><name><surname>Lindström</surname><given-names>J</given-names></name><name><surname>Lakka</surname><given-names>TA</given-names></name><etal></etal></person-group>; <collab>Finnish Diabetes Prevention Study</collab> <article-title>Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study</article-title>. <source>Diabetes</source> <year>2005</year>;<volume>54</volume>:<fpage>158</fpage>–<lpage>165</lpage><pub-id pub-id-type="pmid">15616024</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haffner</surname><given-names>SM</given-names></name><name><surname>Miettinen</surname><given-names>H</given-names></name><name><surname>Gaskill</surname><given-names>SP</given-names></name><name><surname>Stern</surname><given-names>MP</given-names></name></person-group> <article-title>Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans</article-title>. <source>Diabetes</source> <year>1995</year>;<volume>44</volume>:<fpage>1386</fpage>–<lpage>1391</lpage><pub-id pub-id-type="pmid">7589843</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weyer</surname><given-names>C</given-names></name><name><surname>Tataranni</surname><given-names>PA</given-names></name><name><surname>Bogardus</surname><given-names>C</given-names></name><name><surname>Pratley</surname><given-names>RE</given-names></name></person-group> <article-title>Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development</article-title>. <source>Diabetes Care</source> <year>2001</year>;<volume>24</volume>:<fpage>89</fpage>–<lpage>94</lpage><pub-id pub-id-type="pmid">11194248</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>TA</given-names></name><name><surname>Xiang</surname><given-names>AH</given-names></name><name><surname>Peters</surname><given-names>RK</given-names></name><etal></etal></person-group> <article-title>Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women</article-title>. <source>Diabetes</source> <year>2002</year>;<volume>51</volume>:<fpage>2796</fpage>–<lpage>2803</lpage><pub-id pub-id-type="pmid">12196473</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>SE</given-names></name><name><surname>Hull</surname><given-names>RL</given-names></name><name><surname>Utzschneider</surname><given-names>KM</given-names></name></person-group> <article-title>Mechanisms linking obesity to insulin resistance and type 2 diabetes</article-title>. <source>Nature</source> <year>2006</year>;<volume>444</volume>:<fpage>840</fpage>–<lpage>846</lpage><pub-id pub-id-type="pmid">17167471</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Frigerio</surname><given-names>F</given-names></name><name><surname>Maechler</surname><given-names>P</given-names></name></person-group> <article-title>The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress</article-title>. <source>Biochem Soc Trans</source> <year>2008</year>;<volume>36</volume>:<fpage>930</fpage>–<lpage>934</lpage><pub-id pub-id-type="pmid">18793163</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Uusitupa</surname><given-names>M</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name><name><surname>Majander</surname><given-names>H</given-names></name><name><surname>Reijonen</surname><given-names>T</given-names></name><name><surname>Penttilä</surname><given-names>I</given-names></name></person-group> <article-title>Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non-insulin-dependent diabetic subjects</article-title>. <source>Metabolism</source> <year>1988</year>;<volume>37</volume>:<fpage>1092</fpage>–<lpage>1100</lpage><pub-id pub-id-type="pmid">3054433</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzschneider</surname><given-names>KM</given-names></name><name><surname>Carr</surname><given-names>DB</given-names></name><name><surname>Barsness</surname><given-names>SM</given-names></name><name><surname>Kahn</surname><given-names>SE</given-names></name><name><surname>Schwartz</surname><given-names>RS</given-names></name></person-group> <article-title>Diet-induced weight loss is associated with an improvement in beta-cell function in older men</article-title>. <source>J Clin Endocrinol Metab</source> <year>2004</year>;<volume>89</volume>:<fpage>2704</fpage>–<lpage>2710</lpage><pub-id pub-id-type="pmid">15181045</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>DB</given-names></name><name><surname>Utzschneider</surname><given-names>KM</given-names></name><name><surname>Boyko</surname><given-names>EJ</given-names></name><etal></etal></person-group> <article-title>A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominal fat and improves insulin sensitivity but not beta-cell function</article-title>. <source>Diabetes</source> <year>2005</year>;<volume>54</volume>:<fpage>340</fpage>–<lpage>347</lpage><pub-id pub-id-type="pmid">15677490</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manco</surname><given-names>M</given-names></name><name><surname>Panunzi</surname><given-names>S</given-names></name><name><surname>Macfarlane</surname><given-names>DP</given-names></name><etal></etal></person-group>; <collab>Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) Consortium</collab> <article-title>One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study</article-title>. <source>Diabetes Care</source> <year>2010</year>;<volume>33</volume>:<fpage>2090</fpage>–<lpage>2097</lpage><pub-id pub-id-type="pmid">20805281</pub-id></mixed-citation></ref></ref-list></back></article>